Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial
Planned to be branded as EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, KPI-121 showed statistically significant results for primary and also key secondary endpoints in comparison to placebo in